WCG Unveils Results from 2023 Global Site Relationship Benchmark Survey Report
WCG released results from the 2023 CenterWatch Global Site Relationship Benchmark Survey Report. The results show how more than 3,600 representatives from clinical trial sites around the world rate their sponsor and clinical research organization (CRO) relationships as the industry is adjusting to a post-pandemic world.
New to the report this year is the ability for sponsors to evaluate how the CRO that acts on their behalf impacts their site ratings.
Site respondents were asked to rank the overall reputation of 77 sponsors and 34 CROs and rate the relative importance of performance related attributes. They were then requested to identify the organizations they had worked with most during the past two years and rate the performance of those organizations against the attributes.
Both sponsors and CROs received the highest performance scores for the quality of their communication with site staff and their responsiveness to site inquiries, as well as for being professional, organized, and knowledgeable. Areas of improvement based on site recommendations included feedback from sites and study participants/participant groups in protocol design and support for initiatives to help sites build stronger relationships with study volunteers. Recommendations for improvement for CROs included greater efficiency in contract and budget negotiation and receiving ongoing feedback from sites. Sites also recommended more flexibility among both sponsors and CROs to modify budgets.
WCG CenterWatch included many of the same performance attributes in its 2017, 2019, and 2021 surveys so that longitudinal comparisons can be made between those results, and trends evaluated. An in-depth general report, which includes the 2023 sponsor and CRO rankings, is available at https://www.centerwatch.com/products/category/1061-benchmark-reports.
Reference
WCG Unveils Results from 2023 Global Site Relationship Benchmark Survey Report. (2023 May, 24). Cision PR Newswire.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
